Chimeric antigen receptor T-cell therapy-22 (Beijing Yongtai Ruike Biotechnology)

N/A

Report date: 2023/11/13 10:42:25

Base Information

Drug NameChimeric antigen receptor T-cell therapy-22 (Beijing Yongtai Ruike Biotechnology)
Drug Alias NameCAR-T-22
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesImmunotech Applied Science Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Yongtai Rec Biotechnology Co LtdImmunotech Applied Science Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A